Meeting
2012 ASCO Annual Meeting
Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma.
Authors
Koji Sasaki
Beth Israel Medical Center, New York, NY
Koji Sasaki , Gary Lu , Chitra Hosing , Uday R. Popat , Sairah Ahmed , Nina Shah , Qaiser Bashir , Yvonne Dinh , Robert Z. Orlowski , Richard E. Champlin , Muzaffar Qazilbash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8040)
DOI
10.1200/jco.2012.30.15_suppl.8040
Abstract #
8040
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
First Author: Charlotte Pawlyn
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson